Pfizer Animal Health Acquires Embrex

Pfizer Animal Health Acquires Embrex

Pfizer Animal Health has completed its acquisition of Embrex Inc., an international agricultural biotechnology company known for its Inovoject vaccine-delivery systems. The transaction has an aggregate equity purchase price of about $155 million.

Embrex, which is now a wholly-owned subsidiary of Pfizer, will continue to be based in Raleigh-Durham, N.C. Embrex common stock is no longer publicly traded and was de-listed from NASDAQ as the close of the market on Jan. 19.


Leave a Comment


Your email address will not be published. Required fields are marked *


Sign-up for your account with Veterinary Practice News. Your account gives you unlimited free access to our Newsletter Archives and our Digital Editions of Veterinary Practice News.
Please check the box below to confirm you would like to be added to Kenilworth Media’s various e-mail communications (includes e-newsletters, a survey now and then, and offers to the veterinarian industry*).

Leave this empty:

*We do not sell your e-mail address to 3rd parties, we simply forward their offers to you. Of course, you always have the right to unsubscribe from any communications you receive from us, should you change your mind in the future.